Abstract
Purpose There is a wealth of biological evidence that supports the concept that GABAergic inhibition is causal to some genetic generalized epilepsy (GGE) syndromes. Much is known about postsynaptic GABAAR channelopathies, however, the presynaptic determinants are less well-defined such as the role of GABA transporters (SLC6A1 / GAT1; SLC6A11 / GAT3), and GABA biosynthesis biology (GAD1 / GAD67; GAD2 / GAD65).
Methods In response, our study screened four presynaptic GABAergic genes in an international cohort of 708 adults and children with epilepsy, predominantly with GGE syndromes, diagnosed within tertiary epilepsy centers.
Results We identified 15 novel / ultra-rare heterozygous SLC6A1, SLC6A11, GAD2, GAD1 variants in 31 unrelated people with epilepsy, of whom 28 had GGE syndromes. A range of missense, nonsense and splice-site variants were discovered in addition to one digenic case with SLC6A1 & GAD2 variants. SLC6A1 genotypes identified in this study show reduced GAT1 activity, quantitatively linked to epilepsy severity and intellectual disability (ID). Functionally validated SLC6A11 and GAD2 variants are a novel GGE finding, where reduced activity of GAT3 uptake or GAD65 enzyme activity is linked to epilepsy severity. Recessive GAD1 loss-of-function variants have recently been described as the cause of developmental and epileptic encephalopathy cases. Here we present the first two gain-of-function GAD1 variants as a novel GAD67 mechanism in epileptogenesis.
Conclusion This further contributes to the association of GABA proteome with GGE and links subtle quantal GABA sensitivities to the genesis of cortico-thalamic absence seizures in GGE syndromes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Medical Research Council (to M.I.R and R.J.H, G0601585), Epilepsy Research UK (SK.C), and Health and Care Research Wales, specifically Wales Gene Park (M.I.R and SK.C), the Wales Epilepsy Research Network (M.I.R, SK.C, R.H.T) and the Wales Clinical Deanery (R.H.T), NHMRC CRE in Neurocognitive Disorders (1117394, R.J.H), NHMRC Program grants ID 628952 and 1091593 (S.F.B and I.E.S)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Wales Regional Ethics Committee (WREC) 17/WA/0290 23/WA/0002
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
